Physician profile
Ali Feili
NPI 1114300308
$1,132.53
in general payments reported to CMS, 2019-2025
25 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.32 · 2021: $20.85 · 2022: $124 · 2023: $309 · 2024: $330 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $168.02 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $124.09 | 2023-2025 | Valtoco |
| Ge Healthcare | $79.07 | 2023 | |
| Ucb, INC. | $66.68 | 2024 | Rystiggo, Nayzilam |
| Lilly USA, LLC | $65.75 | 2022-2024 | Mounjaro |
| Neurocrine Biosciences, INC. | $57.01 | 2023 | Ingrezza, Ongentys |
| Sanofi Pasteur INC. | $56.84 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $55.01 | 2021-2022 | |
| Janssen Biotech, INC. | $46.52 | 2023 | Tremfya, Stelara, Remicade |
| Teva Pharmaceuticals USA, INC. | $41.41 | 2022-2024 | Austedo Xr |
| Biogen, INC. | $40.95 | 2025 | Vumerity, Tysabri |
| Genentech USA, INC. | $37.64 | 2019-2024 | Ocrevus |
| Emd Serono, INC. | $35.32 | 2022-2025 | |
| Gilead Sciences, INC. | $33.05 | 2025 | Epclusa |
| Vertex Pharmaceuticals Incorporated | $29.81 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otter Pharmaceuticals, LLC | $24.96 | 2024 | Sympazan |
| Edwards Lifesciences Corporation | $24.43 | 2025 | Sapien 3 Ultra Resilia |
| Lundbeck LLC | $22.15 | 2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.95 | 2022 | |
| Octapharma USA, INC. | $20.00 | 2025 | Panzyga |
| Avion Pharmaceuticals | $19.66 | 2023 | Dhivy |
| Ani Pharmaceuticals, INC. | $17.84 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $16.90 | 2024 | Percept Pc Brainsense |
| Pfizer INC. | $15.39 | 2023 | |
| Jazz Pharmaceuticals INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Feili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.